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Alterations of tumour suppressor gene p53 is the most commonly
observed genetic lesion in human cancers (Levine et al, 1991). p53
alterations have a profound impact on tumour biology and the
outcome of patients with many different tumour types. Most p53
gene alterations are mis-sense mutations, and most of those lead to
the synthesis of a mutant protein with a longer than normal half-
life (Lane and Benchimol, 1990; Davidoff et al, 1991), and thus
massive overexpression of the protein product. In many cases, this
accumulated mutant p53 protein can induce a specific humoral
response in patients with various types of cancer (Crawford et al,
1982; Caron de Fromentel et al, 1987; Winter et al, 1992; Lubin et
al, 1993, 1995; Angelopoulou et al, 1994).
In general, anti-p53 antibodies have been found in cancer
patients whose tumours contained p53 mis-sense mutations, but
not in cancer-free populations, or in patients whose tumour had
p53 splice/stop, splice, or frameshift mutations (Winter et al,
1992; Wild et al, 1995). These antibodies recognize both the wild-
type and mutant p53 conformational and denaturation-resistant
epitopes (Davidoff et al, 1992; Schlichtholz et al, 1992).
Furthermore, naturally arising anti-p53 antibodies have been
shown to recognize immunodominant epitopes in the carboxyl-
and amino-terminal domains of the p53 polypeptide and these
locations do not correspond to mutational hot-spots (Lubin et al,
1993; Wild et al, 1995). Although p53 immune responses have
been observed in various types of tumours, it is important to note
that only a proportion of the tumours that bear p53 mis-sense
mutations induce antibodies (Angelopoulou et al, 1994). Thus
other biological properties of the tumour and/or the host may
allow the production of these responses and these other properties
may have clinical significance.
The clinical implications of the development of serum anti-p53
antibodies in cancer patients has been controversial. Most studies
show that the presence of such antibodies predicted a poor
outcome. In breast cancer, patients who developed anti-p53 anti-
bodies exhibited a shortened overall survival than those without
anti-p53 antibodies, and the presence of anti-p53 antibodies was
an independent prognostic factor (Schlichtholtz et al, 1992; Peyrat
et al, 1995). In head and neck squamous cell carcinomas, the
presence of anti-p53 antibodies was significantly associated with
increased risks of relapse and death (Bourhis et al, 1996). On the
other hand, in the newly diagnosed small-cell lung cancer patients
the presence of anti-p53 antibodies was not associated with any
clinical characteristics or prognostic markers (Rosenfeld et al,
1997). The clinical and biological relevance of anti-p53 antibodies
in gastric cancer have not been previously studied in detail.
Gastric cancer is highly prevalent. It was estimated in 1990 to
be the second most frequent cancer in the world (after lung
cancer), with about 900 000 new cases diagnosed every year. In
Serum anti-p53 antibodies in gastric adenocarcinoma
patients are associated with poor prognosis, lymph
node metastasis and poorly differentiated nuclear grade
C-W Wu2,4, Y-Y Lin1, G-D Chen1, C-W Chi3,4, DP Carbone5 and J-Y Chen1,4
1Institute of Biomedical Sciences, Academia Sinica, No. 128, Section 2, Yen-Chiu-Yuan Road, Taipei 11529, Taiwan, Republic of China; Departments of
2Surgery and 3Medical Research, Veterans General Hospital-Taipei; 4National Yang-Ming University; Taiwan, Republic of China; 5Division of Medical Oncology,
Vanderbilt Cancer Center, University of Vanderbilt, Nashville, TN 37232-6838, USA
Summary Mutation of the p53 tumour suppressor gene often leads to the accumulation of mutant p53 protein in tumour cells. Many cancer
patients develop antibodies that recognize the overexpressed p53 protein. The presence of these antibodies is, in some tumour types,
associated with poor prognosis. Gastric cancer is a highly prevalent disease associated with a high rate of mortality, there is a need for
improved clinical and biological markers for disease behaviour. To investigate the clinical relevance of serum anti-p53 antibodies in patients
with gastric adenocarcinoma, we have examined the sera of 501 gastric cancer patients for the presence of serum antibodies against the
p53 protein. By immunoblotting analysis using a cell lysate containing overexpressed p53 protein as well as affinity-purified recombinant p53
protein as antigens, we have detected anti-p53 antibodies in 11.2% (61 of 501) of gastric cancer patients, but in none of 46 cancer-free
individuals. The presence of anti-p53 antibodies was tightly associated with tumours of higher nuclear grade and lymph node metastasis, and
a negative association was found between the presence of anti-p53 antibodies and survival. These results suggest that a preoperative test of
serum anti-p53 antibodies in gastric cancer patients can be useful to identify subset of patients who may need gastrectomy with lymph node
dissection and post-operative adjuvant therapy.
Keywords: gastric adenocarcinoma; serum anti-p53 antibodies; lymph node metastasis; nuclear grade; poor prognosis
483
British Journal of Cancer (1999) 80(3/4), 483–488
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0382
Received 28 May 1998
Revised 6 October 1998
Accepted 21 October 1998
Correspondence to: J-Y Chen, Institute of Biomedical Sciences, Academia
Sinica No. 128, Section 2, Yen-Chiu-Yuan Road, Taipei 11529, Taiwan,
R.O.C..spite of a decreasing incidence, the prognosis for patients diag-
nosed with gastric cancer is dismal (Wu et al, 1997). Gastric
cancer currently ranks as the second most common cause of cancer
death and in some countries, especially those of the Far East such
as China and Japan, it is the leading cause of cancer death. These
factors have prompted the search for novel early diagnostic
markers, improved therapies or prognostic factors that would
enable a more effective treatment regimen to be tailored to specific
groups of patients.
In gastric cancer, the p53 gene is frequently mutated and p53
overexpression is observed in about 50% of tumours (Kakeji et al,
1993; Motojima et al, 1994; Gabbert et al, 1995), and anti-p53
antisera were detected in some of the gastric cancer patients (Wurl
et al, 1997). In this study, we examined a large number of gastric
cancer patients for the presence of humoral antibodies against the
tumour suppressor protein p53 and evaluated the clinical and
biological significance of these antibodies in this disease by corre-
lating their presence with the observed features of the tumour and
clinical outcome.
MATERIALS AND METHODS
Patients and sera
Between February 1988 and August 1996, patients diagnosed with
gastric adenocarcinoma who underwent gastric resection at the
Veterans General Hospital (VGH)-Taipei were enrolled in this
study. Patients with two primary tumours were excluded. A total
of 501 patients were included based on fulfillment of the following
criteria: (a) histologically confirmed disease, (b) available of
preoperative serum, and (c) regular post-surgical follow-up.
Control blood was obtained from forty-six cancer-free individuals
during their physical check-up in the VGH-Taipei. Informed
consent was obtained from each patient. Sera were prepared and
stored at –80°C until use.
p53 Antigens
A pCMV vector expressing human p53 mutant protein with a
single amino acid change at codon 143 from valine to alanine was
kindly provided by Dr Bert Vogelstein (Kern et al, 1992). The
pCMV-p53V143A expression vector was introduced into human
p53-null non-small-cell lung cancer (NSCLC) H1299 cells by
electroporation (Chen et al, 1993). H1299 has a homozygous
5¢-intragenic deletion of p53 gene and produces no p53 mRNA or
protein (Unger et al, 1992; Chen et al, 1993). Forty-eight hours
post-transfection, cells were harvested. Cell lysate was prepared
and used as the source of p53 antigen for immunoblot analysis.
Alternatively, bacterially expressed GST-p53 fusion protein
was prepared for immunoblot analysis. cDNA encoding the full
length p53 protein was in-frame fused to the bacterial glutathione
S-transferase (GST) gene. GST and GST-p53 fusion proteins were
expressed in Escherichia coli DH5a cells and affinity-purified as
described (Sang et al, 1994).
Immunoblot analysis
H1299 cell lysate containing overexpressed mutant p53 protein
(V143A) and the affinity-purified GST-p53 fusion protein were
used as p53 antigens for immunoblot analysis to detect the
presence of anti-p53 antibodies in patients’ sera (Chen et al, 1993).
H1299 whole cell lysates or purified GST-p53 fusion protein were
separated on 10% sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) using a mini-gel apparatus (Hoefer
Mighty Small II). Proteins were then transferred to nitrocellulose
filters (Schleicher and Schuell) followed by blocking with 5%
non-fat dry milk. After drying, the nitrocellulose filters were cut
into 3-mm strips and each strip was subjected to immunoblotting
with each patient’s serum (at 1:200 dilution) as primary and sheep
anti-human Ig horseradish peroxidase (HRP) conjugates (at 1:500
dilution, Amersham, Inc.) as secondary antibodies. A colorimetric
assay was employed to detect the presence of HRP by incubating
the filter strips with phosphate-buffered saline (PBS) containing
3,3¢-diaminobenzidine (0.5 mg ml–1) and 0.015% hydrogen
peroxide. Mouse anti-p53 monoclonal antibody a1801 (Ab-2,
Oncogene Science) was included positive control (at final concen-
tration of 1 mg ml–1).
Statistical analysis
The c2 test and Student’s t-test were adopted to evaluate clinico-
pathologic features that may relate to the status of p53 antibody
development and the biological behaviour of the tumour. The
following factors were considered: age, sex, tumour size, location
of tumour, gross appearance (superficial, localized or infiltrative),
nuclear grade, mode and depth of cancer invasion, Lauren’s,
Ming’s and World Health Organization (WHO) histological classi-
fications, stromal reaction pattern, lymphatic duct invasion,
vascular invasion, lymph node metastasis, liver metastasis and
peritoneal dissemination. To further analyse interactions between
all possible factors, a backward step-wise logistic regression
analysis was performed with anti-p53 antibodies as a dependent
variable. We considered a P-value > 0.05 for likeness of fit in the
final regression model. Survival curves were plotted using the
Kaplan–Meier method. Comparisons were made by the general-
ized Wilcoxon and Mantel Cox tests. Multivariate survival
analysis (BMDP P2L) was based on the Cox multiple step-wise
regression model. A P-value < 0.05 was considered to be statisti-
cally significant. Computation was carried out using BMDP
statistical software (Dixon, 1988).
RESULTS
Detection of serum anti-p53 antibodies in gastric
cancer patients
We evaluated the sera from 501 patients with gastric cancer for
the presence of anti-p53 antibodies. Immunoblot analysis was
performed using the patient sera as primary antibodies against cell
lysates prepared from a p53-null human lung cancer H1299 cell
line transfected with a pCMV vector expressing mutant p53 (with
amino acid change at codon 143 from valine to alanine) and the
same line transfected with the parental plasmid containing no p53
cDNA insert (Kern et al, 1992; Chen et al, 1993). After transfec-
tion with pCMV-p53V143A, H1299 cells expressed a substantial
amount of p53 protein which was readily detected by immunoblot
analyses with mouse anti-p53 monoclonal antibody a1801 (Figure
1). Sera from some of the gastric cancer patients also detected a
band with a migration distance similar to that of p53 protein. The
sera scored as positive were those detecting a 53 kDa signal when
blotted against the lysate prepared from pCMV-p53V143A trans-
fectants but no signal from identically prepared mock-transfected
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pendently confirm that the immune response observed was
directed against the tumour suppressor protein p53, immunoblot
analysis was carried out using affinity-purified GST-p53 protein as
antigen. All of the sera which detected the 53 kDa signal against
the H1299 transfectant were shown to recognize the 80 kDa
GST-p53 fusion protein but not GST protein itself, suggesting that
the immune response was specific for the tumour suppressor p53
protein. Figure 2 shows the immunoblot analysis of GST and
GST-p53 fusion proteins with two p53 antibody-positive (from
patients GC944 and GC389) and one antibody-negative (GC498)
sera. Sera from 61 (12.2%) of the 501 gastric cancer patients
yielded a positive signal toward tumour suppressor p53 protein by
this assay. In contrast, none of the control sera obtained from 46
cancer-free individuals were shown to contain anti-p53 antibodies,
consistent with the extremely low incidence of anti-p53 antibodies
in normal individuals in other reports.
These anti-p53 antibodies elicited in gastric cancer patients
were able to recognize and form complexes with p53 proteins of
both the wild-type and mutant conformations as evidenced by
immunoprecipitation of [35S]-methionine-labelled p53 proteins
synthesized in vitro using a rabbit reticulocyte lysate system by
p53-antibody-positive sera (data not shown).
Correlation between anti-p53 antibodies and
clinicopathologic status
The correlation of anti-p53 antibodies to clinical and tumour
biological parameters was then analysed. As shown in Table 1,
univariate analysis demonstrated that the presence of anti-p53
antibodies is significantly associated with several factors including
large tumour size, ill-defined gross appearance, poorly differen-
tiated nuclear grade, increased depth of invasion, lymphatic duct
invasion and lymph node metastasis. No correlation was found
between the presence of anti-p53 antibodies and the other parame-
ters tested. Logistic regression model (P = 1.000 for goodness of
fit) revealed that lymph node metastasis (P = 0.002) and nuclear
grade (P = 0.003) were the factors independently associated with
the development of these antibodies (data not shown).
All the 501 patients included in this study received only surgical
resection without adjuvant or other types of therapy. The cumula-
tive 5-year survival was 51% in this series. As shown in Figure 3,
there was a significantly poorer survival rate for patients with anti-
p53 antibodies compared to those without them (P = 0.0038). The
median survival of p53-antibody-negative patients was more than
60 months while it was 24 months for p53-antibody-positive
patients. This was also reflected in the 5-year survival rates of 53%
and 31% respectively. Table 2 shows the 5-year survival rates
according to each parameter in the 501 patients. Anti-p53 anti-
bodies (P < 0.0038), along with other tumour- and host-related
factors are associated with decreased survival. These factors
include tumour size (P < 0.0001), ill-defined gross appearance
(P < 0.0001), poorly differentiated nuclear grade (P = 0.0002),
expansive type of invasion and invasion to or through the serosa
(P ≤ 0.0001), higher grade in the three commonly used histopatho-
logic classifications (P ≤ 0.01), stromal reaction (P < 0.0001),
lymphatic and haematogenous spread (P ≤ 0.0001), lymph node
metastasis (P < 0.0001), liver metastasis (P < 0.0001) and peri-
toneal dissemination (P < 0.0001). To identify independent factors
that would predict patients’ outcome, a multivariate analysis was
performed using the Cox regression model. Depth of tumour inva-
sion (P < 0.0001), poorly differentiated histology (by WHO classi-
fication) (P = 0.03), venous invasion (P = 0.0009), lymph node
metastasis (P < 0.0001), liver metastasis (P < 0.0001) and
peritoneal dissemination (P = 0.0099) emerged as independent
prognostic parameters.
DISCUSSION
Development of tumour-associated antibodies against dominant
and recessive oncogenes has been observed in several other
tumour types (Caron de Fromentel et al, 1987; Ben-Mahrez et al,
1990; Sorokine et al, 1991; Winter et al, 1992; Angelopoulou et al,
1994), and in some cases, the presence of anti-p53 antibodies is
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Figure 1 Gastric cancer patients generate humoral antibodies against
tumour suppressor p53. Protein extracts (100 mg per preparative gel)
prepared from NSCLC-H1299 cells expressing a mutant p53 protein were
analysed on a 10% SDS-PAGE gel for immunoblot analysis. After
transblotting, the nitrocellulose filter was cut into strips and each strip was
blotted against a single patient’s serum (at a 1:200 dilution). Sheep anti-
human and sheep anti-mouse Ig HRP conjugates were used as secondary
antibodies respectively. The presence of HRP was detected colorimetrically.
The far right lane represents a positive control (a1801) and p53 signal was
indicated by an arrowhead. Signals with a molecular weight other than
53 kDa were also detected in some patients’ sera on a less frequent basis
Figure 2 Gastric cancer patients developed circulating antibodies specific
for tumour suppressor p53. Affinity-purified GST and GST-p53 fusion
proteins (5 mg protein per lane) were separated by 10% SDS-PAGE and
immunodetected with sera from different patients (GC944, GC389 and
GC498) (at 1:500 dilution) as well as mouse anti-p53 monoclonal antibody
a 1801. HRP-conjugated sheep anti-human or mouse Ig were used as
secondary antibodies (at 1:5000 dilution). HRP was detected by enhanced
chemoluminescence (Amersham, Inc.). The signal of GST-p53 fusion protein
(86 kDa) was indicated by the arrowheadcorrelated to poor prognosis (Schlichtholz et al, 1992; Peyrat et al,
1995; Bourhis et al, 1996). The present study is the first to study a
large number of patients with primary gastric adenocarcinoma and
determine the frequency at which they generate circulating anti-
bodies against p53, and to correlate the development of antibodies
with relevant clinical and biological parameters. Sixty-one of 501
(12.2%) patients were shown to develop these antibodies at levels
sufficient to be detected by the Western blot assay used here. The
presence of serum anti-p53 antibodies in patients with gastric
adenocarcinoma was associated with tumour- and host-related
factors including large tumour size, ill-defined tumour margins,
poorly differentiated nuclear grade, depth of invasion, lymphatic
duct invasion and lymph node metastasis. Anti-p53 antibodies
were associated with a poor patient survival. A logistic regression
model revealed that lymph node metastasis (P = 0.002) and
nuclear grade (P = 0.003) were the factors independently associ-
ated with the development of these antibodies.
It has been reported that mutation of the p53 gene occurs in
approximately 50% of gastric tumours (Kakeji et al, 1993;
Motojima et al, 1994). Our data suggest that approximately
20–30% of gastric cancer patients with tumours bearing p53
gene mutations develop anti-p53 antibodies. This is consistent
with previous observations in patients with other types of cancers
that approximately this proportion of patients with mutations
develop anti-p53 antibodies (Angelopoulou et al, 1994). Thus, not
all of the tumours bearing p53 mis-sense mutations induce anti-
p53 antibodies, suggesting factors other than simple overexpres-
sion of the p53 protein are involved in eliciting the immune
response (Angelopoulou et al, 1994). The fact that 84% (51 of 61)
of the p53-antibody-positive patients displayed lymph node metas-
tasis suggests that involvement of lymph nodes has hitherto unrec-
ognized importance in eliciting the immune response against
overexpressed p53 protein, and that immunological mechanisms
by which the development of anti-p53 antibodies may signify
an aggressive subset of tumours with p53 mutations with the
propensity to involve lymph nodes.
Gastric carcinoma is a world-wide disease with a dismal prog-
nosis. Although surgical resection offers the only prospect of cure,
long-term survival of patients with adenocarcinoma of the
stomach remains poor because of invasion of the tumour through
the muscular layer (advanced cancer) and early lymphatic spread,
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Table 1 Correlation between the status of serum anti-p53 antibodies to
clinicopathological features of gastric cancer patients
Negative Positive
n = 440 n = 61 P-value
(87.8%) (12.2%)
Age (year) 66.3 ± 10.5 67.5 ± 9.3 0.3390
Sex
Men 356 55
Women 84 6 0.0776
Tumour size (cm, mean ± s.d) 5.7 ± 3.4 7.5 ± 2.9 < 0.0001c
Location of tumour
Upper (C) 64 6
Middle (M) 143 21
Lower (A) 233 34 0.6089
Gross appearance
Superficial 139 7
Localized 62 12
Infiltrative 239 42 0.0052c
Nuclear gradea
Well-differentiated 19 0
Moderately differentiated 171 12
Poorly differentiated 250 49 0.0015c
Mode of invasion
Expansive 229 32
Intermediate 122 20
Infiltrative 89 9 0.5205
Depth of invasionb
m, sm 124 7
pm, ss 73 10
se, si 243 44 0.0151c
Japanese histologic type
Papillary + Tubular 201 32
Poorly + Signet + Mucinous 239 29 0.3199
Lauren’s classification
Intestinal type 230 22
Diffuse type 191 35
Unclassified 19 4 0.0579
Ming’s classification
Expanding type 152 22
Infiltrative type 288 39 0.8152
Stromal reaction pattern
Medullary 154 23
Intermediate 159 21
Schirrhous 127 17 0.9171
Lymphatic duct invasion
Negative 129 7
Positive 311 54 0.0033c
Venous invasion
Negative 414 55
Positive 26 6 0.2594
Lymph node metastasis
Negative 184 10
Positive 256 51 0.0001c
Liver metastasis
Negative 418 56
Positive 22 5 0.3568
Peritoneal dissemination
Negative 397 52
Positive 43 9 0.2319
aNuclear grade was determined according to nuclear pleomorphism of tumour cells, well
differentiated: nuclei with minimal variation in size and shape; moderately differentiated:
nuclei with moderate variation in size and shape; poorly differentiated: nuclei with marked
variation in size and shape
bDepth of invasion. m: mucosa; sm: submucosa; pm: proper muscle; ss: subserosa; se:
serosa exposed; si: serosa infiltrated .cStatistically significant.
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Figure 3 Survival curves for gastric cancer patients with and without serum
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Table 2 Association between 5-year survival rates and clinicopathological features of gastric cancer patients
Parameter No. of patients 5-year survival Univariate Multivariate
(total n = 501) (%) P-value P-value
Age
≤ 65 188 54.8
³ 65 313 48.6 0.0952 0.5457
Sex
Men 411 48.5
Women 90 62.7 0.1252 0.9472
Tumour size
< 4 cm 162 83.1
4–8 cm 235 41.1
> 8 cm 104 26.6 < 0.0001c 0.2951
Location of tumour
Upper (C) 70 59.9
Middle (M) 164 53.3
Lower (A) 267 47.2 0.3454 0.8470
Gross appearance
Superficial 146 90.3
Localized 74 64.1
Infiltrative 281 27.9 < 0.0001c 0.0748
Nuclear gradea
Well-differentiated 19 62.2
Moderately differentiated 183 65.4
Poorly differentiated 299 42.0 0.0002c 0.1382
Mode of invasion
Expansive 261 38.1
Intermediate 142 66.3
Infiltrative 98 67.6 0.0001c 0.4905
Depth of invasionb
m, sm 131 95.3
pm, ss 83 72.0
se, si 287 25.0 < 0.0001c < 0.0001c
Japanese histologic type
Papillary + Tubular 233 62.3
Poorly + Signet + Mucinous 268 35.2 0.0001c 0.0320c
Lauren’s classification
Intestinal type 252 63.5
Diffuse type 226 38.1
Unclassified 23 47.1 0.0002c 0.3811
Ming’s classification
Expanding type 174 65.5
Infiltrative type 327 43.6 0.0110c 0.1723
Stromal reaction pattern
Medullary 177 55.1
Intermediate 180 25.4
Schirrhous 144 72.0 < 0.0001c 0.1443
Lymphatic duct invasion
Negative 136 85.4
Positive 365 37.7 < 0.0001c 0.7611
Venous invasion
Negative 469 53.0
Positive 32 23.0 0.0001c 0.0009c
Lymph node metastasis
Negative 194 87.6
Positive 307 29.1 < 0.0001c < 0.0001c
Liver metastasis
Negative 474 53.3
Positive 27 0.0 < 0.0001c < 0.0001c
Peritoneal dissemination
Negative 449 56.6
Positive 52 0.0 < 0.0001c 0.0099c
p53 antibodies
Negative 440 53.2
Positive 61 31.3 0.0038* 0.6396
aNuclear grade was determined according to nuclear pleomorphism of tumour cells, well differentiated: nuclei with minimal variation
in size and shape; moderately differentiated: nuclei with moderate variation in size and shape; poorly differentiated: nuclei with
marked variation in size and shape. bDepth of invasion. m: mucosa; sm: submucosa; pm: proper muscle; ss: subserosa; se: serosa
exposed; si: serosa infiltrated. cStatistically significant.possibly resulting in residual microscopic disease and relapse after
surgical resection (Wu et al, 1996b, 1996c). In this study, 74% of
the tumours were advanced carcinomas and 61% of the patients
had lymph node metastases. Since regional lymph node and recur-
rent nodal involvement have an adverse effect on survival (Wu
et al, 1996a), gastric resection as well as removal of metastatic
lymph nodes are generally considered when attempting curative
resection of adenocarcinomas of the stomach. However, the possi-
bility of increased operative risk through the extension of
lymphadenectomy with controversial clinical benefit raises
concerns about this procedure. In this study, lymph node metas-
tasis and poorly differentiated nuclear grade are independently
associated with these antibodies in multivariate analysis. Kakeji
et al have reported that gastric cancer with p53 overexpression is
highly proliferative and has a high potential for metastasizing to
lymph nodes (Kakeji et al, 1993). If lymph node involvement
precedes the development of anti-p53 antibodies, detection of anti-
bodies would not be a useful early cancer marker as has been
suggested for lung cancer patients (Lubin et al, 1995). The fact
that only 12.2% of gastric cancer patients were sero-positive for
p53-antibodies further excludes its global use as an early diag-
nostic marker for this disease. On the other hand, the identification
of patients with perhaps occult lymph node metastasis and thus
poor prognosis prior to surgical and histopathological detection of
metastasis is in itself a worthwhile goal. In contrast to other pre-
operative image diagnostics, including endoscopic sonography
and computerized tomography, the serological assay of anti-p53
antibodies is non-invasive and easy to perform, and may help to
pinpoint the subset of patients who should be subjected to gastrec-
tomy with lymph node dissection, or it could also be used along
with other established parameters to identify subsets of patients
with poor prognosis who may need post-operative adjuvant
therapy.
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